MedTrace Logo

The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01554046 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-12-18

No results posted yet for this study

Summary

The purpose of this study is to investigate the familial response to Methylphenidate treatment (Ritalin IR) in two aspects: ADHD symptom's improvement and side-effects development.

Conditions

  • Attention Deficit/Hyperactivity Disorder Combined Type
  • ADHD Predominantly Inattentive Type
  • ADHD Predominantly Hyperactivity Type
  • ADHD-not Other Specified

Interventions

DRUG

Methylphenidate- Ritalin IR (Immediate Release)

Duration of treatment- 4 weeks. Dosage- up to 3 times/day. * Ages 6-12, up to 25Kg - 35mg maximum per day. * Ages 6-12, above 25Kg - 50mg maximum per day. * Ages 12-65, above 25Kg - 80mg maximum per day.

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Prof. Doron Gothelf, MD · Sheba Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01554046 on ClinicalTrials.gov